Michail Georgiadis is Professor and head of the Process Systems Engineering Laboratory in the Department of Chemical Engineering at Aristotle University of Thessaloniki. He is also an Honorary Senior Research Fellow at Imperial College London (2017-2021) and Distinguished visiting Professor at Tsinghua University, China (2018-2023). He holds an M.Sc. (1995) and PhD (1998) both from Imperial College London, UK. His research interests include the investigation and application of computer-aided techniques for the modelling, simulation, control and optimisation of systems and processes with emphasis on chemical, biochemical, biomedical, oil and gas, consumer goods and food processes. He has published more than 100 papers in top international peer reviewed journals, more than 120 papers in conference proceedings and 21 chapters in books. He is the co-editor of several books including the 7-volume book series on process systems engineering published by WILEY-VCH (2007-2010), the Elsevier volume on the integration of process design and control (2004) and the Springer volume on Energy systems engineering (2018). He is also the co-author of a book on Energy and Process Integration published by Begell House Inc. His work has received more than 4200 citations with an index of 39 according to google scholar (as of May 2019). Prof. Georgiadis has participated in more than 25 EU-funded collaborative research projects with leading academic and industrial partners from Europe, USA and China.
Fulbright Foundation will provide the opportunity to extend his established collaboration with the Georgia Institute of Technology and Emory University join efforts towards the development and validation of a modelling (in silico) platform that will deliver personalized healthcare clinical products in drug therapy (optimal treatment regime for Acute Myeloid Leukemia). In collaboration with the department of Biomedical Engineering at Georgia Institute of Technology and the Department of Hematology and Medical Oncology at Emory University, an engineered bio-inspired integrated experimental/modelling platform for normal and abnormal hematopoiesis will be studied in order to produce cellular (red blood cell product) and drug (optimal drug treatment) therapies as its output. Furthermore, the collaboration will promote the establishment of academic bridges for young PhD students between the three Institutions.